Revolution Medicines

AACR: Revolution rolls on in pancreatic cancer as RAS wave rises

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, Revolution is not resting on its laurels.

Darren Incorvaia Apr 21, 2026 5:35pm

cancer target detection radiopharma radio

Revolution’s RAS inhibitor hits key goals in ph. 3 cancer trial

Apr 13, 2026 8:00am

Graphic of a line of blocks with percentages on them with one block in yellow showing an arrow increasing

Small molecules are 'resurgent' in orphan drug R&D: Evaluate

Mar 12, 2026 10:30am

Takeda inks $1.7B AI discovery deal with Iambic Therapeutics

Feb 9, 2026 8:00am

Regeneron, Sanofi receive 1- to 2-month priority review vouchers

Oct 17, 2025 8:30am

Parachute over a mountain in Switzerland

GSK chief steps down in stunning move—Chutes & Ladders

Oct 3, 2025 8:30am